Trevi Therapeutics, Inc. is a late stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch).

Gil Yosipovitch, M.D. Joins Trevi Therapeutics Clinical Advisory Board
Noted pruritus key opinion leader is Director of the Temple Itch Center at the Temple University School of Medicine
Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting of the American College of Clinical Pharmacology
Title of Abstract: Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses